ArticleeLife2013
Fitness benefits in fluoroquinolone-resistant Salmonella Typhi in the absence of antimicrobial pressure.
Article in eLife, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.
- Pooled it
- Impacts of feeding preweaned calves milk containing drug residues on the functional profile of the fecal microbiota.Scientific reports · 2018Trial
- Treatment Response in Enteric Fever in an Era of Increasing Antimicrobial Resistance: An Individual Patient Data Analysis of 2092 Participants Enrolled into 4 Randomized, Controlled Trials in Nepal.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Trial
- Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial.The Lancet. Infectious diseases · 2016Trial
- Trial
- Presence of globally prominent multidrug-resistant genotypes ofMicrobial genomics · 2026Article
- Article
- The fitness connection of antibiotic resistance.Frontiers in microbiology · 2025Article
- The role of universal stress protein Usp1413 in meropenem adaptive resistance and environmental stress responses inCurrent research in microbial sciences · 2025Article
- Trends in antimicrobial resistance amongst Salmonella Typhi in Bangladesh: A 24-year retrospective observational study (1999-2022).PLoS neglected tropical diseases · 2024Observational
- Assessing the global risk of typhoid outbreaks caused by extensively drug resistant Salmonella Typhi.Nature communications · 2023Article
- Chance Favors the Prepared Genomes: Horizontal Transfer Shapes the Emergence of Antibiotic Resistance Mutations in Core Genes.Molecular biology and evolution · 2023Article
- Commensal Fitness Advantage May Contribute to the Global Dissemination of Multidrug-Resistant Lineages of Bacteria-The Case of UropathogenicPathogens (Basel, Switzerland) · 2023Article
- Genomic analysis unveils genome degradation events and gene flux in the emergence and persistence of S. Paratyphi A lineages.PLoS pathogens · 2023Article
- Growth kinetics and fitness of fluoroquinolone resistant and susceptibleFrontiers in veterinary science · 2023Article
- Phylogenetic Groups, Pathotypes and Antimicrobial Resistance ofPathogens (Basel, Switzerland) · 2022Article
- Estimating the effect of vaccination on antimicrobial-resistant typhoid fever in 73 countries supported by Gavi: a mathematical modelling study.The Lancet. Infectious diseases · 2022Article
- Physiological Responses of Ribosomal Protein S12 K43 Mutants of Corynebacterium glutamicum.Current microbiology · 2022Article
- Breaking the cycle of malaria treatment failure.Frontiers in epidemiology · 2022Article
- Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents.Molecules (Basel, Switzerland) · 2021Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Fluoroquinolones (FQ) are the recommended antimicrobial treatment for typhoid, a severe systemic infection caused by the bacterium Salmonella enterica serovar Typhi. FQ-resistance mutations in S. Typhi have become common, hindering treatment and control efforts. Using in vitro competition experiments, we assayed the fitness of eleven isogenic S. Typhi strains with resistance mutations in the FQ target genes, gyrA and parC. In the absence of antimicrobial pressure, 6 out of 11 mutants carried a selective advantage over the antimicrobial-sensitive parent strain, indicating that FQ resistance in S. Typhi is not typically associated with fitness costs. Double-mutants exhibited higher than expected fitness as a result of synergistic epistasis, signifying that epistasis may be a critical factor in the evolution and molecular epidemiology of S. Typhi. Our findings have important implications for the management of drug-resistant S. Typhi, suggesting that FQ-resistant strains would be naturally maintained even if fluoroquinolone use were reduced. DOI: http://dx.doi.org/10.7554/eLife.01229.001.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.